טוען...
546. No Difference in MK-8591 and Doravirine Pharmacokinetics After Co-Administration
BACKGROUND: MK-8591 is a novel, highly potent, nucleoside reverse transcriptase translocation inhibitor (NRTTI) that is in development for the treatment of HIV-1 infection. MK-8591 is not expected to be a perpetrator or victim of drug–drug interactions (DDI), as it does not interact with renal or he...
שמור ב:
| הוצא לאור ב: | Open Forum Infect Dis |
|---|---|
| Main Authors: | , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Oxford University Press
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6255630/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofy210.554 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|